Your browser doesn't support javascript.
An update review of emerging small-molecule therapeutic options for COVID-19.
Tian, Dengke; Liu, Yuzhi; Liang, Chengyuan; Xin, Liang; Xie, Xiaolin; Zhang, Dezhu; Wan, Minge; Li, Han; Fu, Xueqi; Liu, Hong; Cao, Wenqiang.
  • Tian D; School of Life Sciences, Jilin University, Changchun, 130012, PR China.
  • Liu Y; Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Liang C; School of Life Sciences, Jilin University, Changchun, 130012, PR China; Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China. Electronic address: chengyuanliang@gmail.com.
  • Xin L; Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Xie X; Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China.
  • Zhang D; Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China.
  • Wan M; School of Medicine and Pharmacy, Shaanxi University of Business & Commerce, Xi'an 712046, PR China.
  • Li H; Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Fu X; School of Life Sciences, Jilin University, Changchun, 130012, PR China.
  • Liu H; Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai, 519030, PR China. Electronic address: sesource_liuhong@163.com.
  • Cao W; Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai, 519030, PR China. Electronic address: sesource_cwq@163.com.
Biomed Pharmacother ; 137: 111313, 2021 May.
Article in English | MEDLINE | ID: covidwho-1062248
ABSTRACT
The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a challenge to global health. At present, many candidate small-molecule therapeutics have been developed that can inhibit both the infection and replication of SARS-CoV-2 and even potentially relieve cytokine storms and other related complications. Meanwhile, host-targeted drugs that inhibit cellular transmembrane serine protease (TMPRSS2) can prevent SARS-CoV-2 from entering cells, and its combination with chloroquine and dihydroorotate dehydrogenase (DHODH) inhibitors can limit the spread of SARS-CoV-2 and reduce the morbidity and mortality of patients with COVID-19. The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin. This review also covers inhibitors of 3C-like protease (3CLpro), papain-like protease (PLpro) and other potentially innovative active ingredient molecules, describing their potential targets, activities, clinical status and side effects.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Molecular Targeted Therapy / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Molecular Targeted Therapy / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2021 Document Type: Article